This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up
by Zacks Equity Research
J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.
Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
AstraZeneca (AZN) Q3 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) surpasses third-quarter estimates for revenues while missing the same for earnings. The company retains 2021 guidance.
Pharma Stock Roundup: AZN, BAYRY Q3 Results, PFE COVID Pill's Strong Efficacy
by Kinjel Shah
AstraZeneca (AZN) and Bayer (BAYRY) announce Q3 results. Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially.
Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3
by Zacks Equity Research
Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan
by Zacks Equity Research
Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.
Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb
by Zacks Equity Research
Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.
AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AstraZeneca's(AZN) third-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on sales numbers of AstraZeneca's COVID-19 vaccine.
Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing
by Zacks Equity Research
Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC. Shares rise in after-market trading.
Organon (OGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Organon (OGN) is set to provide updates on its earnings and revenues when it reports third-quarter 2021 results.
Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially
Three Encouraging News on U.S. Economic Recovery: 5 Top Picks
by Nalak Das
We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.
Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track
by Zacks Equity Research
Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.
Moderna (MRNA) Q3 Earnings Miss, COVID-19 Vaccine Brings $5B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales miss expectations. The company delivers 208 million doses of its COVID-19 vaccine during the third quarter. Stock declines in pre-market.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
5 ETFs Strategies to Play in November
by Sanghamitra Saha
November kicked off on a solid note after a solid October rally. Better-than-expected corporate earnings boosted the U.S. stocks.
Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.
The Zacks Analyst Blog Highlights: PayPal, Merck, Caterpillar, Cisco Systems and TJX Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, Merck, Caterpillar, Cisco Systems and TJX Companies
Top Analyst Reports for PayPal, Merck & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc. (PYPL), Merck & Co., Inc. (MRK), and Caterpillar Inc. (CAT).
Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.